Medidata AI - Using Data to Accelerate Racial Diversity in US Clinical Trials

Historically, US clinical trials have been shown to recruit disproportionately large percentages of White patients, raising concerns about the generalizability of clinical trial results to underrepresented racial minority patient populations. Because of this, the FDA has recently reiterated its guidance stating that clinical trials need to reflect the demographic distribution of the US. 

In this webinar, the Medidata AI team of experts will walk through an analysis of clinical trial data from an industry-leading historical clinical trial data repository, delving into racial disparities across therapeutic areas. This research will explore the current status of racial diversity in US trials and elucidate how various insights can be derived by looking at more granular data in terms of disease area and geography.